Emergen Research recently published a detailed report on the global Liquid Biopsy market formulated through extensive primary and secondary research. The report offers in-depth knowledge and analysis of the Liquid Biopsy market through verified and validated data curated to offer accurate insights. The report also offers a region wise and country wise analysis of the Liquid Biopsy market and contains a detailed analysis of the key elements influencing the growth of the market in the region. The research study also contains historical, current, and forecast estimations for each sector, segment, sub-segment, and regions.
The global liquid biopsy market size is expected to reach USD 7,645.0 Million in 2030 and register a revenue CAGR of 20.3% over the forecast period, according to the latest analysis by Emergen Research. Rise in demand for early cancer detection is a key factor driving global liquid biopsy market revenue growth.
Liquid biopsy is a safe and popular procedure carried out during examination of cancer. The procedure is easy and minimally invasive, allows early detection and diagnosis of cancer, and helps in identification of cancer treatment. In addition, growing popularity of non-invasive techniques is driving private and public financing for research in the field of liquid biopsy, which allow medical professionals to discover various aspects of a tumor through a patient’s blood sample. It facilitates medical professionals to understand, which treatments are suitable for patients.
Development of liquid biopsy has led to a better understanding of molecular diagnostics of circulating tumor DNA. Increased adoption of liquid biopsy in cancer is due to its potential for non-invasive detection of targeted genomic alteration in correspondence to targeted therapy. Non-cancerous application of liquid biopsy includes diagnosis of heart attack and atherosclerosis. Advancement in next-generation sequencing for patients with advanced stages of cancer is driving market growth.
Get Free Sample PDF Copy Of This Report @ https://www.emergenresearch.com/request-sample/34
The report on the Global Liquid Biopsy Market is an investigative study on the key features of the business landscape along with an analysis of the growth opportunities, challenges, threats, drivers and restraints, and limitations of the market. The report also offers insights into the segments, sub-segments, and regions exhibiting promising growth.
The report further sheds light on the competitive landscape of the Liquid Biopsy market to offer the readers an advantage over others. The competitive landscape section of the report talks about the recent advancements in the R&D and technologies undertaken by the prominent players, along with their strategic business expansion plans, product launches, and brand promotions. The report pays special attention to the strategic alliances such as mergers and acquisitions, joint ventures, collaborations, agreements, corporate and government deals, and others adopted by the prominent players of the industry to expand their market presence and gain a substantial market position.
The prominent players profiled in the report are:
Bio-Rad Laboratories, Inc., Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Biocept, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., MDxHealth, Menarini Silicon Biosystems, and Agena Bioscience, Inc.
Furthermore, the report covers a comprehensive overview of the key regions and market segmentation into types and applications. The regional analysis of the global Liquid Biopsy market considers key geographical regions of the world to study different aspects of the market. The market is segmented into key regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Emergen Research has segmented the global liquid biopsy market based on product type, circulating biomarkers, sample type, technology, disease, application, end-use, and region:
- Product Type Outlook (Revenue, USD Million; 2019–2030)
- Assays Kits
- Instruments
- Services
- Circulating Biomarkers Outlook (Revenue, USD Million; 2019–2030)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs)
- Cell-Free DNA (cfDNA)
- Others
- Sample Type Outlook (Revenue, USD Million; 2019–2030)
- Blood Sample
- Urine Sample
- Others
- Technology Outlook (Revenue, USD Million; 2019–2030)
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- Disease Outlook (Revenue, USD Million; 2019–2030)
- Oncology
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma Cancer
- Others
- Non-cancer
- Oncology
- Application Outlook (Revenue, USD Million; 2019–2030)
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring Orthopedics
- End-Use Outlook (Revenue, USD Million; 2019–2030)
- Hospitals & Physician Laboratories
- Reference Laboratories
- Academic & Research Centers
- Others
To know more about the report, visit @ https://www.emergenresearch.com/industry-report/liquid-biopsy-market
Our reports will help you solve the following issues: –
Insecurity about the future:
Our research and insights help our clients to anticipate upcoming revenue compartments and growth ranges. This help our client to invest or divest their assets.
Understanding market opinions:
It is extremely vital to have an impartial understanding of market opinions for a strategy. Our insights help to have a keen view on a market sentiment. We keep this reconnaissance by engaging with Key Opinion Leaders of a value chain of each industry we track.
Understanding the most reliable investment centers:
Our research ranks investments centers of market by considering their future demands, returns and profit margins. Our clients can focus on most prominent investment centers by procuring our market research.
Evaluating potential business partners:
Our research and insights help our clients in identifying compatible business partners.
The research assesses the recent progress in the competitive landscape including collaborations, joint ventures, product launches, acquisitions and mergers as well as investments in the sector for research and development.
Thank you for reading our report. Customization of this report is available as per the client’s requirements. Please connect with us to know more about the report, and our team will ensure you get the report tailored according to your needs.
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
The post Liquid Biopsy Market to be Worth $7,645.0 Million by 2030: Emergen Research appeared first on Market O Graphics.
